ID   AHR_RAT                 Reviewed;         853 AA.
AC   P41738; O88930; O89105;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   25-MAR-2003, sequence version 2.
DT   24-JUL-2024, entry version 183.
DE   RecName: Full=Aryl hydrocarbon receptor;
DE            Short=Ah receptor;
DE            Short=AhR;
DE   Flags: Precursor;
GN   Name=Ahr;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RC   STRAIN=Fischer 344, and Sprague-Dawley; TISSUE=Liver, and Placenta;
RX   PubMed=8065918; DOI=10.1093/nar/22.15.3038;
RA   Carver L.A., Hogenesch J.B., Bradfield C.A.;
RT   "Tissue specific expression of the rat Ah-receptor and ARNT mRNAs.";
RL   Nucleic Acids Res. 22:3038-3044(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 236-251 AND
RP   702-708, FUNCTION, AND TISSUE SPECIFICITY.
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=7812217;
RA   Elferink C.J., Whitlock J.P. Jr.;
RT   "Dioxin-dependent, DNA sequence-specific binding of a multiprotein complex
RT   containing the Ah receptor.";
RL   Receptor 4:157-173(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-497.
RC   STRAIN=Han/Wistar, Long Evans, and Sprague-Dawley;
RX   PubMed=9658193; DOI=10.1124/mol.54.1.86;
RA   Pohjanvirta R., Wong J.M.Y., Li W., Harper P.A., Tuomisto J., Okey A.B.;
RT   "Point mutation in intron sequence causes altered carboxyl-terminal
RT   structure in the aryl hydrocarbon receptor of the most 2,3,7,8-
RT   tetrachlorodibenzo-p-dioxin-resistant rat strain.";
RL   Mol. Pharmacol. 54:86-93(1998).
RN   [4]
RP   INDUCTION.
RX   PubMed=11755109; DOI=10.1016/s0006-2952(01)00820-6;
RA   Franc M.A., Pohjanvirta R., Tuomisto J., Okey A.B.;
RT   "In vivo up-regulation of aryl hydrocarbon receptor expression by 2,3,7,8-
RT   tetrachlorodibenzo-p-dioxin (TCDD) in a dioxin-resistant rat model.";
RL   Biochem. Pharmacol. 62:1565-1578(2001).
RN   [5]
RP   REVIEW ON ROLE IN CELL CYCLE.
RX   PubMed=12213388; DOI=10.1016/s0009-2797(02)00069-8;
RA   Puga A., Xia Y., Elferink C.;
RT   "Role of the aryl hydrocarbon receptor in cell cycle regulation.";
RL   Chem. Biol. Interact. 141:117-130(2002).
CC   -!- FUNCTION: Ligand-activated transcription factor that enables cells to
CC       adapt to changing conditions by sensing compounds from the environment,
CC       diet, microbiome and cellular metabolism, and which plays important
CC       roles in development, immunity and cancer (PubMed:7812217). Upon ligand
CC       binding, translocates into the nucleus, where it heterodimerizes with
CC       ARNT and induces transcription by binding to xenobiotic response
CC       elements (XRE). Regulates a variety of biological processes, including
CC       angiogenesis, hematopoiesis, drug and lipid metabolism, cell motility
CC       and immune modulation. Xenobiotics can act as ligands: upon xenobiotic-
CC       binding, activates the expression of multiple phase I and II xenobiotic
CC       chemical metabolizing enzyme genes (such as the CYP1A1 gene). Mediates
CC       biochemical and toxic effects of halogenated aromatic hydrocarbons.
CC       Next to xenobiotics, natural ligands derived from plants, microbiota,
CC       and endogenous metabolism are potent AHR agonists. Tryptophan (Trp)
CC       derivatives constitute an important class of endogenous AHR ligands.
CC       Acts as a negative regulator of anti-tumor immunity: indoles and
CC       kynurenic acid generated by Trp catabolism act as ligand and activate
CC       AHR, thereby promoting AHR-driven cancer cell motility and suppressing
CC       adaptive immunity. Regulates the circadian clock by inhibiting the
CC       basal and circadian expression of the core circadian component PER1.
CC       Inhibits PER1 by repressing the CLOCK-BMAL1 heterodimer mediated
CC       transcriptional activation of PER1. The heterodimer ARNT:AHR binds to
CC       core DNA sequence 5'-TGCGTG-3' within the dioxin response element (DRE)
CC       of target gene promoters and activates their transcription (By
CC       similarity). {ECO:0000250|UniProtKB:P35869,
CC       ECO:0000269|PubMed:7812217}.
CC   -!- SUBUNIT: Homodimer (By similarity). Heterodimer; efficient DNA binding
CC       requires dimerization with another bHLH protein. Interacts with ARNT;
CC       the heterodimer ARNT:AHR binds to core DNA sequence 5'-TGCGTG-3' within
CC       the dioxin response element (DRE) of target gene promoters and
CC       activates their transcription (By similarity). Binds MYBBP1A (By
CC       similarity). Interacts with coactivators including SRC-1, RIP140 and
CC       NOCA7, and with the corepressor SMRT. Interacts with NEDD8 and IVNS1ABP
CC       (By similarity). Interacts with BMAL1. Interacts with HSP90AB1 (By
CC       similarity). Interacts with TIPARP; leading to mono-ADP-ribosylation of
CC       AHR and subsequent inhibition of AHR (By similarity).
CC       {ECO:0000250|UniProtKB:P30561, ECO:0000250|UniProtKB:P35869}.
CC   -!- INTERACTION:
CC       P41738; P41739: Arnt; NbExp=2; IntAct=EBI-1162880, EBI-1162920;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P30561}. Nucleus
CC       {ECO:0000250|UniProtKB:P30561}. Note=Initially cytoplasmic; upon
CC       binding with ligand and interaction with a HSP90, it translocates to
CC       the nucleus. {ECO:0000250|UniProtKB:P30561}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Long;
CC         IsoId=P41738-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P41738-2; Sequence=VSP_002091;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues tested including brain,
CC       heart, kidney, liver, lung, spleen, skeletal muscle and thymus.
CC       {ECO:0000269|PubMed:7812217, ECO:0000269|PubMed:8065918}.
CC   -!- INDUCTION: Induced or repressed by TGF-beta in a cell-specific fashion.
CC       Repressed by dioxin, retinoic acid, and TPA.
CC       {ECO:0000269|PubMed:11755109}.
CC   -!- DOMAIN: The PAS 1 domain is essential for dimerization and also
CC       required for AHR:ARNT heterodimerization.
CC       {ECO:0000250|UniProtKB:P30561}.
CC   -!- PTM: Mono-ADP-ribosylated, leading to inhibit transcription activator
CC       activity of AHR. {ECO:0000250|UniProtKB:P35869}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U09000; AAA56897.1; -; mRNA.
DR   EMBL; U04860; AAA19451.1; -; mRNA.
DR   EMBL; AF082124; AAC35168.1; -; mRNA.
DR   EMBL; AF082125; AAC35169.1; -; mRNA.
DR   EMBL; AF082126; AAC35170.1; -; mRNA.
DR   PIR; S58375; S58375.
DR   AlphaFoldDB; P41738; -.
DR   SMR; P41738; -.
DR   BioGRID; 247719; 4.
DR   IntAct; P41738; 2.
DR   STRING; 10116.ENSRNOP00000006618; -.
DR   BindingDB; P41738; -.
DR   ChEMBL; CHEMBL5400; -.
DR   iPTMnet; P41738; -.
DR   PhosphoSitePlus; P41738; -.
DR   PaxDb; 10116-ENSRNOP00000006618; -.
DR   UCSC; RGD:2074; rat. [P41738-1]
DR   AGR; RGD:2074; -.
DR   RGD; 2074; Ahr.
DR   eggNOG; KOG3560; Eukaryota.
DR   InParanoid; P41738; -.
DR   PhylomeDB; P41738; -.
DR   Reactome; R-RNO-211945; Phase I - Functionalization of compounds.
DR   Reactome; R-RNO-211976; Endogenous sterols.
DR   Reactome; R-RNO-211981; Xenobiotics.
DR   Reactome; R-RNO-8937144; Aryl hydrocarbon receptor signalling.
DR   PRO; PR:P41738; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0034751; C:aryl hydrocarbon receptor complex; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0034753; C:nuclear aryl hydrocarbon receptor complex; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0052869; F:arachidonic acid omega-hydroxylase activity; IMP:RGD.
DR   GO; GO:0017162; F:aryl hydrocarbon receptor binding; ISO:RGD.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISO:RGD.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0070888; F:E-box binding; ISS:UniProtKB.
DR   GO; GO:0051879; F:Hsp90 protein binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0004879; F:nuclear receptor activity; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0051087; F:protein-folding chaperone binding; ISO:RGD.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; ISS:UniProtKB.
DR   GO; GO:0017025; F:TBP-class protein binding; ISO:RGD.
DR   GO; GO:0001094; F:TFIID-class transcription factor complex binding; ISO:RGD.
DR   GO; GO:0015643; F:toxic substance binding; IDA:RGD.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISO:RGD.
DR   GO; GO:0001223; F:transcription coactivator binding; ISO:RGD.
DR   GO; GO:0046222; P:aflatoxin metabolic process; IEP:RGD.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0001782; P:B cell homeostasis; ISO:RGD.
DR   GO; GO:0008015; P:blood circulation; ISO:RGD.
DR   GO; GO:0001568; P:blood vessel development; ISO:RGD.
DR   GO; GO:0048514; P:blood vessel morphogenesis; ISO:RGD.
DR   GO; GO:0001974; P:blood vessel remodeling; ISO:RGD.
DR   GO; GO:0001569; P:branching involved in blood vessel morphogenesis; ISO:RGD.
DR   GO; GO:0043010; P:camera-type eye development; ISO:RGD.
DR   GO; GO:0019933; P:cAMP-mediated signaling; ISO:RGD.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISO:RGD.
DR   GO; GO:0000902; P:cell morphogenesis; ISO:RGD.
DR   GO; GO:1904613; P:cellular response to 2,3,7,8-tetrachlorodibenzodioxine; IDA:UniProtKB.
DR   GO; GO:1904682; P:cellular response to 3-methylcholanthrene; ISO:RGD.
DR   GO; GO:0071320; P:cellular response to cAMP; ISO:RGD.
DR   GO; GO:1904322; P:cellular response to forskolin; ISO:RGD.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; IEP:RGD.
DR   GO; GO:0071219; P:cellular response to molecule of bacterial origin; ISO:RGD.
DR   GO; GO:0097237; P:cellular response to toxic substance; IMP:RGD.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0003243; P:circumferential growth involved in left ventricle morphogenesis; ISO:RGD.
DR   GO; GO:0048732; P:gland development; ISO:RGD.
DR   GO; GO:0072102; P:glomerulus morphogenesis; ISO:RGD.
DR   GO; GO:0002376; P:immune system process; ISO:RGD.
DR   GO; GO:0060993; P:kidney morphogenesis; ISO:RGD.
DR   GO; GO:0001889; P:liver development; ISO:RGD.
DR   GO; GO:0002260; P:lymphocyte homeostasis; ISO:RGD.
DR   GO; GO:1903170; P:negative regulation of calcium ion transmembrane transport; IDA:RGD.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IDA:RGD.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; IDA:RGD.
DR   GO; GO:0033689; P:negative regulation of osteoblast proliferation; IDA:RGD.
DR   GO; GO:0003085; P:negative regulation of systemic arterial blood pressure; ISO:RGD.
DR   GO; GO:0002841; P:negative regulation of T cell mediated immune response to tumor cell; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0045906; P:negative regulation of vasoconstriction; ISO:RGD.
DR   GO; GO:0046209; P:nitric oxide metabolic process; IEP:RGD.
DR   GO; GO:0097267; P:omega-hydroxylase P450 pathway; IMP:RGD.
DR   GO; GO:0001541; P:ovarian follicle development; IMP:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0045793; P:positive regulation of cell size; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0040010; P:positive regulation of growth rate; ISO:RGD.
DR   GO; GO:0045899; P:positive regulation of RNA polymerase II transcription preinitiation complex assembly; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0035166; P:post-embryonic hemopoiesis; ISO:RGD.
DR   GO; GO:0030850; P:prostate gland development; ISO:RGD.
DR   GO; GO:0034504; P:protein localization to nucleus; IMP:RGD.
DR   GO; GO:1903409; P:reactive oxygen species biosynthetic process; IMP:RGD.
DR   GO; GO:0002819; P:regulation of adaptive immune response; ISS:UniProtKB.
DR   GO; GO:0030888; P:regulation of B cell proliferation; ISO:RGD.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:RGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0048608; P:reproductive structure development; ISO:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IMP:RGD.
DR   GO; GO:0009636; P:response to toxic substance; ISO:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IDA:UniProtKB.
DR   GO; GO:0048536; P:spleen development; ISO:RGD.
DR   GO; GO:0043029; P:T cell homeostasis; ISO:RGD.
DR   GO; GO:0048771; P:tissue remodeling; IEP:RGD.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0001944; P:vasculature development; ISO:RGD.
DR   GO; GO:0006805; P:xenobiotic metabolic process; IEA:InterPro.
DR   CDD; cd11436; bHLH-PAS_AhR; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; Helix-loop-helix DNA-binding domain; 1.
DR   Gene3D; 3.30.450.20; PAS domain; 2.
DR   InterPro; IPR039091; AHR/AHRR.
DR   InterPro; IPR033348; AHR_bHLH.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   InterPro; IPR013655; PAS_fold_3.
DR   PANTHER; PTHR10649; ARYL HYDROCARBON RECEPTOR; 1.
DR   PANTHER; PTHR10649:SF9; ARYL HYDROCARBON RECEPTOR; 1.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   Pfam; PF08447; PAS_3; 1.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; HLH, helix-loop-helix DNA-binding domain; 1.
DR   SUPFAM; SSF55785; PYP-like sensor domain (PAS domain); 2.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 1.
PE   1: Evidence at protein level;
KW   Activator; ADP-ribosylation; Alternative splicing; Biological rhythms;
KW   Cell cycle; Cytoplasm; Direct protein sequencing; DNA-binding; Nucleus;
KW   Receptor; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation.
FT   PROPEP          1..9
FT                   /evidence="ECO:0000250|UniProtKB:P30561"
FT                   /id="PRO_0000013464"
FT   CHAIN           10..853
FT                   /note="Aryl hydrocarbon receptor"
FT                   /id="PRO_0000013465"
FT   DOMAIN          26..79
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   DOMAIN          116..179
FT                   /note="PAS 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          273..340
FT                   /note="PAS 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          346..384
FT                   /note="PAC"
FT   REGION          1..38
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          37..65
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000250|UniProtKB:P35869"
FT   REGION          49..81
FT                   /note="Required for maintaining the overall integrity of
FT                   the AHR:ARNT heterodimer and its transcriptional activity"
FT                   /evidence="ECO:0000250|UniProtKB:P35869"
FT   REGION          116..124
FT                   /note="Required for maintaining the overall integrity of
FT                   the AHR:ARNT heterodimer and its transcriptional activity"
FT                   /evidence="ECO:0000250|UniProtKB:P30561"
FT   REGION          264..266
FT                   /note="Required for maintaining the overall integrity of
FT                   the AHR:ARNT heterodimer and its transcriptional activity"
FT                   /evidence="ECO:0000250|UniProtKB:P30561"
FT   REGION          429..451
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           12..15
FT                   /note="Nuclear localization signal 1"
FT                   /evidence="ECO:0000250|UniProtKB:P35869"
FT   MOTIF           36..41
FT                   /note="Nuclear localization signal 2"
FT                   /evidence="ECO:0000250|UniProtKB:P35869"
FT   MOTIF           63..71
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250|UniProtKB:P35869"
FT   VAR_SEQ         142..376
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8065918"
FT                   /id="VSP_002091"
FT   VARIANT         497
FT                   /note="V -> A (in strain: Han/Wistar, Han/Wistar-dv, Han/
FT                   Wistar-siv and Han/Wistar-liv)"
FT                   /evidence="ECO:0000269|PubMed:9658193"
FT   VARIANT         766..808
FT                   /note="Missing (in strain: Han/Wistar-dv)"
FT   VARIANT         809..853
FT                   /note="FQSPSILNEAYSADLSSIGHLQTAAHLPRLAEAQPLPDITPSGFL -> IRA
FT                   FYRE (in strain: Han/Wistar-siv and Han/Wistar-liv)"
FT   CONFLICT        74
FT                   /note="S -> T (in Ref. 1; AAA56897)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        659
FT                   /note="A -> V (in Ref. 1; AAA56897)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        679..682
FT                   /note="YSLF -> ICLL (in Ref. 1; AAA56897)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        739
FT                   /note="A -> V (in Ref. 1; AAA56897)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        744
FT                   /note="D -> E (in Ref. 1; AAA56897)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        770
FT                   /note="A -> G (in Ref. 1; AAA56897)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        787
FT                   /note="H -> D (in Ref. 1; AAA56897)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        794
FT                   /note="Q -> H (in Ref. 2; AAA19451)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   853 AA;  96227 MW;  4EED0EE795FF1327 CRC64;
     MSSGANITYA SRKRRKPVQK TVKPVPAEGI KSNPSKRHRD RLNTELDRLA SLLPFPQDVI
     NKLDKLSVLR LSVSYLRAKS FFDVALKSTP ADRSRGQDQC RAQVRDWQDL QEGEFLLQAL
     NGFVLVVTAD ALVFYASSTI QDYLGFQQSD VIHQSVYELI HTEDRAEFQR QLHWALNPSQ
     CTDSAQGVDE THGLPQPAVY YTPDQLPPEN TAFMERCFRC RLRCLLDNSS GFLAMNFQGR
     LKYLHGQNKK GKDGALLPPQ LALFAIATPL QPPSILEIRT KNFIFRTKHK LDFTPIGCDA
     KGQLILGYTE VELCNKGSGY QFIHAADMLH CAESHIRMIK TGESGMTVFR LLAKHSRWRW
     VQSNARLIYR NGRPDYIIAT QRPLTDEEGR EHLQKRSMTL PFMFATGEAV LYEISSPFSP
     IMDPLPIRTK SNTSRKDWAP QSTPSKDSFH PNSLMSALIQ QDESIYLCPP SSPAPLDSHF
     LMDSMSECGS WQGSFAVASN EALLKHEEIR HTQDVNLTLS GGPSELFPDN KNNDLYSIMR
     NLGIDFEDIR SMQNEEFFRT DSSGEVDFKD IDITDEILTY VQDSLNNSTL LNSACQQQPV
     SQHLSCMLQE RLQLEQQQQL QQQHPTQTLE PQRQLCQVEV PQHELGQKTK HMQVNGMFAS
     WNPAPPVSFS CPQQERKHYS LFSGLQGTAQ EFPYKSEVDS MPYTQNFAPC NQSLLPEHSK
     GTQLDFPGRD FERSLHPNAS NLEDFVSCLQ VPENQRHGIN SQSAMVSPQA YYAGAMSMYQ
     CQAGPQHTPV DQMQYSPEIP GSQAFLSKFQ SPSILNEAYS ADLSSIGHLQ TAAHLPRLAE
     AQPLPDITPS GFL
//
